search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- 1. Accounting Policies
- 2. Financial risk management
- 3. Segmental information
- 4. Exceptional operating items
- 5. Operating profit/(loss)
- 6. Employees and Directors
- 7. Finance Income and costs
- 8. Taxation on Loss on ordinary activites
- 9. Loss for the financial year
- 10. Earnings/(Loss) per Share
- 11. Goodwill
- 12. Intangible assets
- 13. Property, plant and equipment
- 14. Investments
- 15. Inventories
- 16. Trade and other receivables
- 17. Trade and other payables
- 18. Borrowings
- 19. Non-current tax
- 20. Financial Instruments
- 21. Called-up share capital
- 22. Options and Warrants over Shares of Sinclair Pharma plc
- 23. Share-based payments
- 24. Other Reserves
- 25. Cash Flows from Operating Activities
- 26. Operating lease commitments
- 27. Capital Commitments
- 28. Related Party Transactions
- corporate advisors
21. CALLED-UP SHARE CAPITAL
2008 |
2007 |
2008 |
2007 |
|
| Group and Company | Number |
Number |
£'000 |
£'000 |
| Authorised | ||||
| Ordinary shares of 1p | 125,000,000 |
125,000,000 |
1,250 |
1,250 |
| Issued and fully paid | ||||
| Ordinary shares of 1p | ||||
| At 1 July | 93,478,980 |
93,291,215 |
935 |
933 |
| Allotted on exercise of share options | — |
130,000 |
— |
1 |
| Allotted on acquisition of additional shares | ||||
| from minority interest in Sinclair Pharma AB | — |
57,765 |
— |
1 |
| At 30 June | 93,478,980 |
93,478,980 |
935 |
935 |
See note 22 for details of share options and warrants over ordinary shares.